Nexien BioPharma, Inc. (NXEN)
OTCMKTS
· Delayed Price · Currency is USD
0.0095
+0.0005 (5.56%)
Apr 24, 2025, 3:50 PM EDT
Nexien BioPharma Company Description
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States.
The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018.
Nexien BioPharma, Inc. is based in Glendale, Colorado.
Nexien BioPharma, Inc.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Richard Greenberg |
Contact Details
Address: 4340 East Kentucky Avenue Glendale, Delaware 80246 United States | |
| Phone | 303 495 7583 |
| Website | nexienbiopharma.com |
Stock Details
| Ticker Symbol | NXEN |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | US65343D1000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard S. Greenberg | Founder, Chief Executive Officer, Executive Vice President and Chairman |
| Evan L. Wasoff CPA | Chief Financial Officer |
| Robert I. Goldfarb Esq., J.D. | Chief Operating Officer |